XJPX
7707
Market cap39mUSD
Oct 09, Last price
232.00JPY
1D
2.20%
1Q
13.17%
Jan 2017
-43.00%
IPO
187.31%
Name
Precision System Science Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Precision System Science Co., Ltd. (PSS), along with its subsidiaries, specializes in the development, production, and global distribution of automated and physicochemical instruments, software, and various related goods, serving both the Japanese domestic market and international clientele. The company's product line includes essential plastic consumables designed for its automated systems, a range of reagents, and sophisticated automated systems for nucleic acid extraction and veterinary biochemical analysis. PSS also offers geneLEAD, a specialized instrument crucial for molecular diagnostics. Furthermore, the firm is actively engaged in the research, development, and practical application within the in vitro diagnostics sector, particularly focusing on genetic and protein testing. Established in 1985, Precision System Science Co., Ltd. is headquartered in Matsudo, Japan.
Key people
Yu Sugiyama
President, Representative Director · since 2024
Akihiro Furukawa
Managing Director, Chief Executive Officer of Subsidiary · since 2019
Ryoji Karinaga
Director · since 2024
Susumu Kimura
Director · since 2024
Daisuke Ogiwara
Independent Director · since 2020
Naoyuki Tamura
Independent Director · since 2025
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||